Skip to Content
Cancer Diagnosis Program
Contact NExT
Show menu
Search this site
Last Updated: 03/04/21

Molecular Signatures of Lung Cancer

U01 CA114771

David P. Carbone, M.D., Ph.D.
Vanderbilt-Ingram Cancer Center

Dr. Carbone’s project focused on refining and evaluating molecular signatures that address critical clinical issues in lung cancer. The project evaluated diagnostic, prognostic, and predictive signatures developed by members of this team. These studies will combine data generated using several comprehensive technologies including mutation analysis, determination of DNA amplification, gene expression analysis, proteomics profiling and single nucleotide polymorphism (SNP) analysis of a number of genes known to be important in therapeutic response.

Collaborators:

  • The project includes investigators from Vanderbilt University, University of Michigan, Dana Farber Cancer Institute, five NCI lung SPOREs at University of Colorado, University of Texas Southwestern Medical Center, MD Anderson, University of Pittsburgh, Duke University, and UCLA, SWOG, the Spanish Lung Cancer Group, and the Institut Catalia d'Oncologia in Barcelona. The project has bioinformatic and statistical support from a number of the participating institutions.

Projects:

  • Evaluate serum and plasma protein profiles of patients to develop a diagnostic marker panel.
  • Test proteomic and gene expression signatures predictive of outcome and nodal involvement on early stage tumors.
  • Combine data for a variety of analytical methods to develop profiles identifying response to standard and targeted therapies.
  • Reduce the derived signatures to robust, practical clinical assays.

Featured Publications:

Taguchi F et al (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 99: 838-846. PMID: 17551144

This publication from the Carbone SPECS project describes a proteomic test, now commercially available as the Veristrat® assay.

Amann, J. M., J. W. Lee, et al. (2010) Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 5(2): 169-178. PMCID: 3087978

Carbone, D. P., J. S. Salmon, et al. (2010) VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 69(3): 337-340. PMCID: 2891357